6533b833fe1ef96bd129b811
RESEARCH PRODUCT
Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study.
Wolf-karsten HofmannSergio SiragusaUlrich GermingCarlo AulRainer HaasKatharina GötzeGiuseppe A. PalumboSabine BlumR.f. SchlenkSilvana MagrinBarbara HildebrandtMichael LübbertJudith NeukirchenJoerg HasfordAristoteles GiagounidisUwe PlatzbeckerAndrea KündgenMichael LausekerGuido KobbeSamuela Martinosubject
OncologyAdultMalemedicine.medical_specialtyPediatricsCancer ResearchScoring systemAllogeneic transplantationSurvivalAdolescenturologic and male genital diseasesRisk AssessmentIPSS; IPSS-R; MDS; Prognosis; Survival; WPSS; Hematology; Oncology; Cancer ResearchRisk categoryYoung AdultRisk FactorsInternal medicinemedicineMDSHumansIn patientAgedAged 80 and overIPSS-Rbusiness.industryIPSSInduction chemotherapyReproducibility of ResultsHematologyMiddle AgedPrognosisSurvival AnalysisMulticenter studyOncologyInternational Prognostic Scoring SystemLeukemia MyeloidMyelodysplastic SyndromesAcute DiseaseMultivariate AnalysisDisease ProgressionWPSSFemalebusinessdescription
The revised IPSS (IPSS-R) was developed aiming at a better prognostication, taking into account patients treated with best supportive care. We herein validated this model on the basis of data from 1314 patients who received BSC only as well as patients who underwent induction chemotherapy (n=214) or allogeneic transplantation (n=167). We could demonstrate a clear distinction of the IPSS-R risk categories with regard to survival and risk of AML evolution in all patient cohorts. When comparing IPSS-R, IPSS, WHO prognostic scoring system (WPSS) and Duesseldorf score, the best results regarding the ability to predict survival were obtained by the IPSS-R.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2013-09-10 | Leukemia research |